Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334607 · ClinicalTrials.gov registry record · Phase 3
Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 484
- Enrollment target
NCT00334607 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 484 participants.
The verdict
NCT00334607, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 484 participants
- Enrollment target
Study Summary
The aim of this this study is to confirm absence of immune interference between HRV vaccine and routine infant vaccinations currently in use in the USA.
Interventions
- BIOLOGICAL 2-dose oral live attenuated G1P[8] human rotavirus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334607
The ClinicalTrials.gov registry entry for NCT00334607 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-dose oral live attenuated G1P[8] human rotavirus vaccine is the first listed.
NCT00334607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00334607 about?
NCT00334607 is a clinical study titled "Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA". The aim of this this study is to confirm absence of immune interference between HRV vaccine and routine infant vaccinations currently in use in the USA.
What is the current status of trial NCT00334607?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 484 participants. The study started on 2006-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00334607?
The interventions under investigation include: 2-dose oral live attenuated G1P[8] human rotavirus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00334607?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.